Target intelligence / Profile preview

Diphthamide biosynthesis protein 1 (DPH1)

Target
DPH1
Molecular classification
Enzyme, Iron–sulfur cluster protein, S-adenosylmethionine-dependent transferase
01

Overview

Diphthamide biosynthesis protein 1 (DPH1) is an **iron–sulfur cluster enzyme** critical for the first step of diphthamide biosynthesis—a unique post-translational modification on a specific histidine residue (His715 in humans) of translation elongation factor 2 (EF2)[1][2]. This modification is essential for translational fidelity and is the direct target of bacterial toxins such as **diphtheria toxin** and **Pseudomonas exotoxin A**, which ADP-ribosylate diphthamide and thereby inhibit protein synthesis[1][2]. DPH1, together with DPH2 (and in coordination with DPH3 and DPH4 for electron transfer), catalyzes the transfer of a 3-amino-3-carboxypropyl group from S-adenosylmethionine to EF2, forming the key carbon–carbon bond required for diphthamide[1][2][3][5]. DPH1 is evolutionarily conserved across eukaryotes and archaea, and its function is linked to maintenance of translational accuracy and cellular stress responses, including regulation of TOR/mTOR signaling pathways that control growth and metabolism[4][5]. In humans, DPH1 also functions as a **tumor suppressor** (notably as OVCA1 in ovarian cancer), and loss-of-function mutations cause a congenital DPH1 deficiency syndrome with developmental abnormalities[2]. Due to its essential role in translation and cellular viability, **DPH1 is not a typical direct drug target**, but its loss or functionally altered variants have important biological and clinical implications. No approved drugs target DPH1 directly, but inhibitors of diphthamide synthesis or DPH1 function would broadly impact protein synthesis and cellular viability, representing a significant therapeutic challenge[2][3].

Other names
2-(3-amino-3-carboxypropyl)histidine synthase subunit 1DPH2LDPH2L1OVCA1DEDSSHDPH2-like 1OVCA1 (ovarian cancer-associated gene 1 protein)S-adenosyl-L-methionine:L-histidine 3-amino-3-carboxypropyltransferase 1diphtheria toxin resistance protein 1candidate tumor suppressor in ovarian cancer 1diphthamide biosynthesis protein 2 homolog-like 1
02

Mechanism of action

Drugs/toxins ADP-ribosylate diphthamide (on EF2, which requires DPH1 function for biosynthesis), thereby inhibiting protein synthesis

03

Biological functions

Posttranslational histidine modificationProtein translation fidelity (via modification of elongation factor 2)Regulation of cell growth and protein synthesisMaintenance of ribosomal translation fidelityPositive regulator of mTOR/TOR signaling
04

Disease associations

Cancer (tumor suppressor in ovarian cancer)Inherited metabolic disorders (DPH1 deficiency syndrome)Susceptibility to bacterial toxins (diphtheria toxin and Pseudomonas exotoxin A)Other (potential developmental disorders due to translational defects)
05

Safety considerations

Potential risk of developmental disorders and translation defects with DPH1 inhibitiongeneral translation impairment is toxic to normal cellsno current drugs target DPH1 directly, but loss of function is associated with severe consequences in model systems and patients
06

Interacting drugs

None established in clinical use

2 more in the full profile.

07

Biomarkers

Loss or mutation of DPH1 (e.g. as a tumor suppressor locus OVCA1 in ovarian cancer)Diphtamide-modified/non-modified EF2 may serve as a functional readout in specialized research

Beyond the preview

Go deeper on Diphthamide biosynthesis protein 1 (DPH1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diphthamide biosynthesis protein 1 (DPH1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call